← Back to headlines
Eli Lilly Reports Positive Phase 1b Results for Verve-102
Eli Lilly announced positive results from its Phase 1b study of Verve-102, a new investigational drug, indicating promising progress in its clinical development.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
